A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Clinical trial NCT05593497 · RECRUITING

Trial details

NCT number: NCT05593497
Sponsor: VA Office of Research and Development
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High-Risk Prostate Cancer

Start date: 2024-05-31
Primary completion: 2027-05-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.